StreetAlpha.app
Home › Stocks › ARAY

Accuray Inc (ARAY)

$2.08
▼ −2.12%
LAST CLOSE · NOV 20

Accuray makes radiation therapy systems, planning software and imaging tools for hospitals and cancer centers. It last closed at $2.08 on Nov 20, down 2.12% on the day. The next earnings report for ARAY is expected around Wed, Feb 3, 2027, after the close. For the quarter ended Sep 2026, ARAY reported EPS of $0.07 on revenue of $86.5M, with revenue down 7.9% from a year ago. Over its last 8 reports the stock moved an average of 12.5% the session after earnings. Over the last 12 months ARAY insiders bought $134K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ARAY in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ARAY.

Key Stats

Last 12 months
Results
Revenue
$394.5M
−12.5% vs a year ago
Net income
−$17.4M
−4.4% margin
EPS (diluted)
−$0.15
Free cash flow
−$27.1M
−6.9% margin
Valuation
Market cap
$249.3M
120.2M shares
P/E
–
No P/E while losing money
Price to sales
0.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$42.3M
At Sep 30
Debt
$101.7M
At Sep 30
Shareholder equity
$53.1M
Shares outstanding
120.2M
At Oct 31
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2022: $429.9M$429.9MFY2022FY2023: $447.6M$447.6MFY2023FY2024: $446.6M$446.6MFY2024FY2025: $458.5M$458.5MFY2025FY2026: $401.9M$401.9MFY2026

From ARAY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Feb 3
Estimated date · After the close
Reported EPS
$0.07
Quarter ended Sep 2026
Year ago EPS
-$0.18
Same quarter last year
Revenue
$86.5M
−7.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.02Dec '24Mar 2025: -$0.01Mar '25Jun 2025: $0.01Jun '25Sep 2025: -$0.18Sep '25Dec 2025: -$0.11Dec '25Mar 2026: -$0.09Mar '26Jun 2026: -$0.01Jun '26Sep 2026: $0.07Sep '26Latest $0.07
Revenue by quarter
Dec 2024: $116.2MDec '24Mar 2025: $113.2MMar '25Jun 2025: $127.5MJun '25Sep 2025: $93.9MSep '25Dec 2025: $102.2MDec '25Mar 2026: $104.8MMar '26Jun 2026: $100.9MJun '26Sep 2026: $86.5MSep '26Latest $86.5M
How ARAY moved after its last 8 reports
Average move the session after a report ±12.5%
Nov 4, 2026After the close−16.9%
Aug 19, 2026After the close−0.8%
May 6, 2026After the close−38.5%
Feb 4, 2026After the close−20.7%
Oct 20, 2025Time not announced0.0%
Aug 13, 2025After the close−2.0%
Apr 30, 2025After the close−12.9%
Feb 5, 2025After the close+8.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ARAYStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ARAY
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ARAY

Technical Analysis

ARAY · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 96% below its 20 day and 234% below its 50 day average. It is 510% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 19), oversold. The nearest support is the 52 week low at $2.05, and the nearest resistance the Pivot at $2.10.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 29.7%/day
Key levels
$45.2052 week high+2073.1%
$12.65200 day average+508.2%
$8.80100 day average+323.1%
$6.9250 day average+232.7%
$6.58Swing high (Nov 4)+216.3%
$4.0720 day average+95.7%
$2.16Pivot R1+3.8%
$2.10Pivot+1.0%
$2.08Last close
$2.0552 week low−1.4%
$2.02Pivot S1−2.9%
Indicators
RSI (14)19.38Oversold below 30Oversold
MACD-1.37Below its signal lineBearish
Stochastic1.1Near the bottom of its rangeOversold
ADX (14)37.6Trending down
Williams %R-99.5Oversold below −80, overbought above −20Oversold
CCI (20)-105.0Oversold below −100, overbought above 100Oversold
Rate of change−52.8%Change over 10 sessionsBearish
ATR (14)$0.62Typical daily range, 29.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARAY

What happened before

See how ARAY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ARAY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ARAY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ARAYHow many large options trades hit ARAY, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ARAY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼18 buying vs 79 selling
  • ●Held by funds -0.4 pts
  • ▼Funds holding -19
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding93112−17.0%
In funds' top 1010–
Held by funds59.1%59.6%−0.4 pts
New / increased10 / 826 / 35−70.5%
Reduced / sold out51 / 2828 / 41+14.5%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARAY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ARAY Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$134K2 buys · 1 insider
Sold$00 sales · 0 insiders
2026-02 bought $134KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Feb 20Steven F MayerDirectorBuy54,875$0.56$31K
Feb 19Steven F MayerDirectorBuy195,125$0.53$103K
Nov 19, 2025Neve Stephen R. LaCEOBuy20,000$0.97$19K
Jun 13, 2025Joseph E WhittersDirectorBuy50,000$1.25$63K
Every insider buy and sale for ARAY over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ARAY insider trades →

From SEC Form 4 filings by ARAY's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARAY is in one of them and how their past ARAY trades turned out.

ARAY in the AI portfolios
Loading…

ARAY News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARAY in an article yet. Here's the latest on the wider market.

ARAY in the news

About Accuray

Accuray is a radiation therapy company based in Madison, Wisconsin. It makes radiation treatment systems, including the CyberKnife robotic platform and a range of helical systems, along with treatment planning software, imaging technology and related services such as installation, training and customer support. Its customers include hospitals, cancer centers and clinicians, including radiation oncologists and neurosurgeons, who use the equipment to treat tumors and selected neurologic or endocrine disorders where clinically appropriate.

Headquarters
Madison, WI